Parkinson's disease
Conditions
Interventions
OP-2024 will be administered as a single oral dose, alone and in combination with magnesium oxide or rabeprazole.
Sponsors
Hashimoto Hideaki
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1) Healthy Japanese male. 2) BMI at time of screening is >= 18.5 to < 25.0. 3) Written informed consent to participate in this trial can be obtained.
Exclusion criteria
Exclusion criteria: 1) History of allergies to any component of the investigational product, drug, or food. 2) Subjects with or at risk for angle-closure glaucoma. 3) Subjects with pheochromocytoma or paraganglioma, or other catecholamine-secreting tumors. 4) History of neuroleptic malignant syndrome or nontraumatic rhabdomyolysis. 5) History of diseases affecting the gastrointestinal tract, liver, kidneys, or heart that may influence the absorption, distribution, metabolism, or excretion of drugs. 6) History of major surgery involving the gastrointestinal tract, including gastrectomy, gastrostomy, or bowel resection (excluding appendectomy).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pharmacokinetics | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety | — |
Contacts
Public ContactHideaki Hashimoto
OHARA Pharmaceuitical Co., Ltd
Outcome results
None listed